Revelation Biosciences Inc (NASDAQ: REVB), a clinical-stage life sciences company, on Monday announced positive safety and biomarker data from its Phase 1 clinical study of Gemini (RVL-HV02), Revelation's proprietary TLR4 agonist. The study met its primary endpoint, confirming the safety and tolerability of escalating doses of Gemini and identified a maximum tolerated dose in healthy volunteers. Statistically significant dose-dependent upregulation of key biomarkers was observed, demonstrating Gemini's immunostimulatory preconditioning effect.
Conducted in Australia with 40 healthy participants aged 18 to 55, the study evaluated escalating doses of intravenously administered Gemini. Results showed significant dose-dependent changes in circulatory biomarkers, reflecting the expected pharmacology of TLR4 stimulation. Significant increases in interleukin-1RA, neutrophil gelatinase lipocalin, c-reactive protein and IL-6 were observed without significant increases in TNF-α and IL-1β, indicating Gemini's potential to reprogram the innate immune response.
Gemini was well-tolerated, with adverse events including transient headache, chills, body aches and vomiting, consistent with preclinical findings. The study's results and the established maximum tolerated dose will guide dose level selection in a planned Phase 1b study in chronic kidney disease patients.
The TLR4 agonist is being developed as a preconditioning therapy for acute kidney injury due to cardiac surgery and to reduce post-surgical infection severity. Revelation's preclinical studies suggest Gemini can reduce the severity and duration of acute kidney injury and bacterial infections and prevent kidney tissue scarring in chronic kidney disease models.
Revelation Biosciences focuses on harnessing trained immunity for disease prevention and treatment, with ongoing programs evaluating Gemini for various indications.
Boston Scientific's FARAPULSE Pulsed Field Ablation system receives Japanese regulatory approval
Genetesis' CardioFlux Magnetocardiograph receives Health Canada approval
Avacta Group presents positive Phase 1 data for AVA6000 at ESMO Congress
Novartis reports Leqvio demonstrates LDL-C lowering in Phase III trial
Hyundai Bioscience to conduct Phase 3 trial for high-risk COVID-19 patients
Bayer launches Phase II study for chronic kidney disease treatment
Johnson & Johnson agrees acquisition of V-Wave
AbCellera expands collaboration with Lilly
AstraZeneca's Calquence combo improves 1L CLL progression-free survival
Destiny Pharma's XF-73 nasal gel reduces antibiotic use in cardiac surgery patients